 Kazia Therapeutics Ltds ASX:KZA FRA:NV9 NASDAQ:KZIA valuation has increased to A346 million or A2.68 per share from A301 million or A2.32 per share following the companys in-licensing of EVT801, a novel small molecule inhibitor of VEGFR3, from Evotec SE FRA:EVT OTCMKTS:EVTCY A new research report from Edison Group analyst Nathaniel Calloway highlighted the expansion of the companys product pipeline to include EVT801 as a good strategic fit while paxalisib is in the clinic. He said: Strategically, this is an important deal for Kazia, because it enables it to expand the pipeline to multiple drugs. 